AstraZeneca Launches Phase II Trial of Anti-TIGIT NSCLC Therapy

AstraZeneca dosed the first patient in the second phase of an ongoing trial assessing a PD-1/TIGIT bispecific antibody in patients with stage III unresectable or stage IV non-small cell lung cancer.